Market closed
REGENXBIO/$RGNX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Ticker
$RGNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
344
Website
REGENXBIO Metrics
BasicAdvanced
$360M
-
-$5.00
1.24
-
Price and volume
Market cap
$360M
Beta
1.24
52-week high
$28.80
52-week low
$6.56
Average daily volume
943K
Financial strength
Current ratio
3.051
Quick ratio
2.717
Long term debt to equity
36.957
Total debt to equity
48.375
Interest coverage (TTM)
-52.13%
Management effectiveness
Return on assets (TTM)
-26.03%
Return on equity (TTM)
-71.87%
Valuation
Price to revenue (TTM)
4.12
Price to book
1.19
Price to tangible book (TTM)
1.19
Price to free cash flow (TTM)
-1.881
Growth
Revenue change (TTM)
-15.14%
Earnings per share change (TTM)
-16.56%
3-year revenue growth (CAGR)
-3.26%
3-year earnings per share growth (CAGR)
-1.12%
What the Analysts think about REGENXBIO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
REGENXBIO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
REGENXBIO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
REGENXBIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $360M as of February 25, 2025.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of February 25, 2025.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.